The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Meta–Analysis of Interferon Randomized Trials in the Treatment of Viral Hepatitis C: Effects of Dose and Duration
Open accessAbstract
The aims of this study were to evaluate the benefits of higher doses or of longer duration in comparison with a standard interferon regimen (3 MU three times per week for 6 months) in chronic hepatitis C, and to assess the efficacy of interferon in acute hepatitis C. Meta–analysis made use of the Peto et al. and the Der Simonian and Laird methods, with heterogeneity and sensitivity analyses. In chronic hepatitis, a total of 17 trials versus controls and of 16 trials comparing different interferon regimens were included. Standard regimen, 3 MU three times per week for 6 months, was associated with an increase of the complete alanine transaminase (ALT) response rate and sustained (ALT) response rate by 45% (95% confidence interval: 35% to 55%; P < .001) and 21% (13% to 28%; P < .001), respectively, with the natural course being less than 2% of spontaneous responses. There was a significant dose effect (6 vs. 3 MU three times per week) upon the sustained response rate at 12 months, with a mean 17% increase (7% to 28%; P < .001), but not at 6 months. There was a significant duration effect (12 vs. 6 months) upon the sustained response rate both at the dose of 3 MU with a mean of 16% (9% to 23%; P < .001), and at the dose of 6 MU three times per week with a mean of 20% (7% to 33%; P = .003). In acute hepatitis C, 3 months of interferon treatment showed significant efficacy versus controls (4 trials), upon the complete ALT response (69% vs. 29%; P < .001), the sustained response rate during the 12 months following treatment (53% vs. 32%; P = .02), and hepatitis C virus (HCV)–RNA clearance (41% vs. 4%; P < .001). The best efficacy/risk ratio was in favor of 3 MU three times per week for at least 12 months in patients with chronic hepatitis C who had never been treated with interferon. Patients with acute hepatitis should be treated with at least 3 MU three times per week for 3 months.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Bedossa, P. (1994) · Hepatology · doi:10.1002/hep.1840200104 · Cited by 2,003
Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa
Davis, G. L., Balart, L. A., Schiff, E. R., Lindsay, K., Bodenheimer, H. C., Perrillo, R. P., Carey, W., Jacobson, I. M., Payne, J., Dienstag, J. L., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911303212203 · Cited by 1,633
Meta-Analyses of Randomized Controlled Trials
Sacks, H. S., Berrier, J., Reitman, D., Ancona-Berk, V. A., & Chalmers, T. C. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702193160806 · Cited by 1,250
Recombinant Interferon Alfa Therapy for Chronic Hepatitis C
Di Bisceglie, A. M., Martin, P., Kassianides, C., Lisker-Melman, M., Murray, L., Waggoner, J., Goodman, Z., Banks, S. M., & Hoofnagle, J. H. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911303212204 · Cited by 1,212
Methods for combining randomized clinical trials: Strengths and limitations
Demets, D. L. (1987) · Statistics in Medicine · doi:10.1002/sim.4780060325 · Cited by 1,027
Poynard, T., Bedossa, P., Chevallier, M., Mathurin, P., Lemonnier, C., Trepo, C., Couzigou, P., Payen, J. L., Sajus, M., Costa, J. M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506013322201 · Cited by 458
Self-citationQuantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy
Hagiwara, H., Hayashi, N., Mita, E., Takehara, T., Kasahara, A., Fusamoto, H., & Kamada, T. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)91025-d · Cited by 377
Interferon for non-A, non-B chronic hepatitis
Tine', F., Magrin, S., Craxi', A., & Pagliaro, L. (1991) · Journal of Hepatology · doi:10.1016/0168-8278(91)90814-r · Cited by 286
The retrieval of randomized clinical trials in liver disease from the medical literature
Poynard, T., & Conn, H. O. (1985) · Controlled Clinical Trials · doi:10.1016/0197-2456(85)90103-5 · Cited by 150
Self-citation
Cited by
McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., Goodman, Z. D., Ling, M.-H., Cort, S., & Albrecht, J. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392101 · Cited by 3,465
Natural history of liver fibrosis progression in patients with chronic hepatitis C
Poynard, T., Bedossa, P., & Opolon, P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07642-8 · Cited by 3,011
Self-citationPoynard, T., Marcellin, P., Lee, S. S., Niederau, C., Minuk, G. S., Ideo, G., Bain, V., Heathcote, J., Zeuzem, S., Trepo, C., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)07124-4 · Cited by 2,318
Self-citationDavis, G. L., Esteban-Mur, R., Rustgi, V., Hoefs, J., Gordon, S. C., Trepo, C., Shiffman, M. L., Zeuzem, S., Craxi, A., Ling, M.-H., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392102 · Cited by 1,282
Peginterferon Alfa-2a in Patients with Chronic Hepatitis C
Zeuzem, S., Feinman, S. V., Rasenack, J., Heathcote, E. J., Lai, M.-Y., Gane, E., O'Grady, J., Reichen, J., Diago, M., Lin, A., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012073432301 · Cited by 1,220
Egger, M., Jüni, P., Bartlett, C., Holenstein, F., & Sterne, J. (2003) · Health Technology Assessment · doi:10.3310/hta7010 · Cited by 1,181
Yoshida, H., Shiratori, Y., Moriyama, M., Arakawa, Y., Ide, T., Sata, M., Inoue, O., Yano, M., Tanaka, M., Fujiyama, S., et al. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-3-199908030-00003 · Cited by 1,096
The Treatment of Chronic Viral Hepatitis
Hoofnagle, J. H., & Di Bisceglie, A. M. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701303360507 · Cited by 946
Pegylation: A Novel Process for Modifying Pharmacokinetics
Harris, J. M., Martin, N. E., & Modi, M. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140070-00005 · Cited by 913
Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C
Liang, T. J., Rehermann, B., Seeff, L. B., & Hoofnagle, J. H. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-4-200002150-00008 · Cited by 868
Neuropsychiatric Adverse Effects of Interferon-??: Recognition and Management
Raison, C. L., Demetrashvili, M., Capuron, L., & Miller, A. H. (2005) · CNS Drugs · doi:10.2165/00023210-200519020-00002 · Cited by 483
Neuropsychiatric Symptoms Associated With Hepatitis C and Interferon Alpha: A Review
Dieperink, E., Willenbring, M., & Ho, S. B. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.6.867 · Cited by 422
Wang, Y.-S., Youngster, S., Grace, M., Bausch, J., Bordens, R., & Wyss, D. F. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00027-3 · Cited by 420
Bonkovsky, H. L., & Woolley, M. J. (1999) · Hepatology · doi:10.1002/hep.510290124 · Cited by 398
Side effects of α interferon in chronic hepatitis C
Dusheiko, G. (1997) · Hepatology · doi:10.1002/hep.510260720 · Cited by 397
American Gastroenterological Association Technical Review on the Management of Hepatitis C
Dienstag, J. L., & McHutchison, J. G. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.010 · Cited by 384
Relation of Interferon Therapy and Hepatocellular Carcinoma in Patients with Chronic Hepatitis C
Imai, Y., Kawata, S., Tamura, S., Yabuuchi, I., Noda, S., Inada, M., Maeda, Y., Shirai, Y., Fukuzaki, T., Kaji, I., et al. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-2-199807150-00005 · Cited by 338
Schaefer, M., Schmidt, F., Folwaczny, C., Lorenz, R., Martin, G., Schindlbeck, N., Heldwein, W., Soyka, M., Grunze, H., Koenig, A., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50031 · Cited by 324
Polyak, S. J., Khabar, K. S. A., Paschal, D. M., Ezelle, H. J., Duverlie, G., Barber, G. N., Levy, D. E., Mukaida, N., & Gretch, D. R. (2001) · Journal of Virology · doi:10.1128/jvi.75.13.6095-6106.2001 · Cited by 323
Piton, A., Poynard, T., Imbert-Bismut, F., Khalil, L., Delattre, J., Pelissier, E., Sansonetti, N., & Opolon, P. (1998) · Hepatology · doi:10.1002/hep.510270505 · Cited by 301
Self-citationRacial differences in responses to therapy with interferon in chronic hepatitis C
Reddy, R. K., Hoofnagle, J. H., Tong, M. J., Lee, W. M., Pockros, P., Heathcote, J. E., Albert, D., & Joh, T. (1999) · Hepatology · doi:10.1002/hep.510300319 · Cited by 291
Di Bisceglie, A. M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)07361-3 · Cited by 288
Expression of Hepatitis C Virus Proteins Inhibits Signal Transduction through the Jak-STAT Pathway
Heim, M. H., Moradpour, D., & Blum, H. E. (1999) · Journal of Virology · doi:10.1128/jvi.73.10.8469-8475.1999 · Cited by 287
Poynard, T., McHutchison, J., Davis, G. L., Esteban-Mur, R., Goodman, Z., Bedossa, P., & Albrecht, J. (2000) · Hepatology · doi:10.1053/jhep.2000.19347 · Cited by 280
Self-citationViral kinetics in patients with chronic hepatitis C treated with standard or peginterferon α2a
Zeuzem, S., Lee, J., Herrmann, E., Fricke, J., Neumann, A. U., Modi, M., Colucci, G., & Roth, W. K. (2001) · Gastroenterology · doi:10.1053/gast.2001.24006 · Cited by 270
10-year follow-up after interferon-α therapy for chronic hepatitis C
Lau, D. T., Kleiner, D. E., Ghany, M. G., Park, Y., Schmid, P., & Hoofnagle, J. H. (1998) · Hepatology · doi:10.1002/hep.510280430 · Cited by 266
Treatment of Hepatitis C Infection in Injection Drug Users
Backmund, M., Meyer, K., Von Zielonka, M., & Eichenlaub, D. (2001) · Hepatology · doi:10.1053/jhep.2001.25882 · Cited by 256
Mendlewicz, J., Kriwin, P., Oswald, P., Souery, D., Alboni, S., & Brunello, N. (2006) · International Clinical Psychopharmacology · doi:10.1097/00004850-200607000-00005 · Cited by 229
Metadata
- Authors
- Poynard, T., Leroy, V, Cohard, M., Thevenot, T., Mathurin, P., Opolon, P., & Zarski, J. P.
- Venue
- Hepatology
- Published
- 1996-10
- Volume
- 24
- Issue
- 4
- Pages
- 778-789
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2069633422
- Cited by
- 671
- References
- 21
- FWCI
- 40.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.